ArticleJTO clinical and research reports2026
Outcomes and Toxicities of Definitive Radiation Therapy for Unresected Thymic Malignancies.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Introduction: Thymic malignancies are primarily managed with surgery. Some patients are medically inoperable or technically unresectable. We report the characteristics and outcomes of patients with unresected thymic tumors treated with definitive radiation therapy (RT) at our institution. Methods: Patients treated with curative-intent RT for unresected thymic tumors between 1997 and 2023 were identified. Age at diagnosis, sex, histology, Masaoka or TNM stage, WHO classification, reason for no resection, RT dose and fractionation, presence of paraneoplastic syndrome, chemotherapy use, and toxicities were extracted. Overall and local failure-free survival, patterns of progression, and treatment toxicities were assessed. This retrospective chart review did not require informed consent. Results: A total of 33 consecutive patients were identified (16 females and 17 males) with a median age of 61 years at diagnosis. Overall, 22 patients had thymoma and 11 had thymic carcinoma. T stage was T2 (one), T3 (seven), and T4 (25); N stage was N0 (15), N1 (one), and N2 (17); M stage was M0 (21), M1a (eight), and M1b (four). Median tumor size was 8.1 cm. Three patients were medically inoperable; 30 were technically unresectable. Of the 33 patients, 29 received chemotherapy. The median RT dose was 60 Gy in 2 Gy fractions.Furthermore, 6% developed a grade 3 toxicity and 9% developed grade 2 pneumonitis. No grade 4/5 toxicities were observed. The 2-year overall survival was 69% (95% confidence interval [CI]: 52-92) and 5-year overall survival was 56% (95% CI: 37-85). The 3- and 5-year local failure rates were 20% (95% CI: 6.9-39). Conclusions: In the most advanced stage and one of the largest reports to date, definitive chemo-RT provides high rates of local control in patients with unresected thymic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.